wedge
REFERENCES for BIOTROFIX - Preclinical CRO & Contract Research Firm
REFERENCES for BIOTROFIX - Preclinical CRO & Contract Research Firm BIOTROFIX - Premier Preclinical CRO - Stroke, Alzheimer's, ALS, TBI Research - Seth P. Finklestein, M.D., CEO REFERENCES for BIOTROFIX - Preclinical CRO & Contract Research Firm Finklestein SP references, publications, articles on preclinical research, drug development, cardiac disease and preclinical drug discovery - Seth P. Finklestein M.D.
REFERENCES for BIOTROFIX - Preclinical CRO & Contract Research Firm REFERENCES for BIOTROFIX - Preclinical CRO & Contract Research Firm REFERENCES for BIOTROFIX - Preclinical CRO & Contract Research Firm REFERENCES for BIOTROFIX - Preclinical CRO & Contract Research Firm REFERENCES for BIOTROFIX - Preclinical CRO & Contract Research Firm
 
Home
greybar
The Company
greybar
Preclinical Research Services
PK/PD Studies
Acute Stroke
Stroke Recovery
Alzheimer's Disease
Amyotrophic Lateral Sclerosis
Traumatic Brain Injury
Spinal Cord Injury
Muscular Dystrophy
Myocardial Infarction
Peripheral Vascular Disease
Others
Will Travel Services
greybar
The Team
greybar
News from Biotrofix
greybar
Publications
greybar
Contact Us


Well-equipped CRO laboratory
 

Glial growth factor 2 promotes functional recovery with treatment initiated up to 7 days after permanent focal ischemic stroke.

1. Neuropharmacology. 2010 Dec;59(7-8):640-9. Epub 2010 Aug 4.

Glial growth factor 2 promotes functional recovery with treatment initiated up to
7 days after permanent focal ischemic stroke.

Iaci JF, Ganguly A, Finklestein SP, Parry TJ, Ren J, Saha S, Sietsma DK, Srinivas
M, Vecchione AM, Caggiano AO.

Acorda Therapeutics Inc., 15 Skyline Drive, Hawthorne, NY 10532, USA.
jiaci@acorda.com

Comment in
Neuropharmacology. 2010 Dec;59(7-8):650-3.

Neuregulins are a family of growth factors essential for normal cardiac and
nervous system development. The EGF-like domain of neuregulins contains the
active site which binds and activates signaling cascades through ErbB receptors.
A neuregulin-1 gene EGF-like fragment demonstrated neuroprotection in the
transient middle cerebral artery occlusion (MCAO) stroke model and drastically
reduced infarct volume (Xu et al., 2004). Here we use a permanent MCAO rat model
to initially compare two products of the neuregulin-1 gene and also assess levels
of recovery with acute versus delayed time to treatment. In the initial study
full-length glial growth factor 2 (GGF2) and an EGF-like domain fragment were
compared with acute intravenous delivery. In a second study GGF2 only was
delivered starting at 24h, 3 days or 7 days after permanent ischemia was induced.
In both studies daily intravenous administration continued for 10 days. Recovery
of neurological function was assessed using limb placing and body swing tests.
GGF2 had similar functional improvements compared to the EGF-like domain fragment
at equimolar doses, and a higher dose of GGF2 demonstrated more robust functional
improvements compared to a lower dose. GGF2 improved sensorimotor recovery with
all treatment paradigms, even enhancing recovery of function with a delay of 7
days to treatment. Histological assessments did not show any associated reduction
in infarct volume at either 48 h or 21 days post-ischemic event. Neurorestorative
effects of this kind are of great potential clinical importance, given the
difficulty of delivering neuroprotective therapies within a short time after an
ischemic event in human patients. If confirmed by additional work including
additional data on mechanism(s) of improved outcome with verification in other
stroke models, one can make a compelling case to bring GGF2 to clinical trials as
a neurorestorative approach to improving outcome following stroke injury.
PMID: 20691195 [PubMed - indexed for MEDLINE]

 
 
Home | The Company | Preclinical Research Services | The Team | News | Publications | Contact Us | Site Map
wedgeBiotrofix, Inc. 604 Webster Street, Needham, MA 02494 Tel: 781-786-8890 Fax: 781-465-6061


Biotrofix is a premier preclinical contract research organization specializing in animal models of CNS, cardiac and vascular disease. With years of experience, both academic, commercial, clients throughout the biotech and pharmaceutical industries, Biotrofix delivers industry-leading preclinical CRO services, including rodent models of acute stroke and stroke recovery, preclinical CRO services for Alzheimer's Disease, transgenic animal models for ALS, as well as CRO services for brain injury, preclinical CRO services for spinal cord injury and related cardiac drug discovery and development.